DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of “Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has been given an average rating of “Buy” by the twenty-four ratings firms that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $394.95.

DXCM has been the subject of a number of recent research reports. Guggenheim increased their price objective on DexCom from $385.00 to $395.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Oppenheimer initiated coverage on DexCom in a report on Tuesday, July 28th. They issued a “buy” rating and a $445.00 price objective for the company. Cowen upped their price target on shares of DexCom from $430.00 to $450.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Canaccord Genuity upped their price target on shares of DexCom from $435.00 to $500.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Robert W. Baird upped their price target on shares of DexCom from $296.00 to $373.00 and gave the company an “outperform” rating in a research report on Wednesday, April 29th.

NASDAQ DXCM opened at $435.54 on Tuesday. The company has a market capitalization of $41.70 billion, a price-to-earnings ratio of 198.88, a PEG ratio of 4.74 and a beta of 0.79. DexCom has a twelve month low of $138.28 and a twelve month high of $446.50. The stock has a fifty day simple moving average of $410.52 and a 200 day simple moving average of $325.07. The company has a quick ratio of 5.41, a current ratio of 7.58 and a debt-to-equity ratio of 1.28.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, July 28th. The medical device company reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.48. The business had revenue of $451.80 million during the quarter, compared to the consensus estimate of $415.21 million. DexCom had a return on equity of 29.01% and a net margin of 11.93%. DexCom’s quarterly revenue was up 34.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.08 earnings per share. Research analysts expect that DexCom will post 2.45 earnings per share for the current fiscal year.

In related news, EVP Steven Robert Pacelli sold 1,531 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $396.74, for a total value of $607,408.94. Following the transaction, the executive vice president now owns 51,482 shares of the company’s stock, valued at approximately $20,424,968.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Shelly Ramasamy Selvaraj sold 400 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $404.05, for a total transaction of $161,620.00. The disclosure for this sale can be found here. Insiders have sold a total of 63,293 shares of company stock worth $24,266,963 in the last three months. Insiders own 0.69% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sunbelt Securities Inc. bought a new position in DexCom in the 4th quarter valued at about $3,062,000. Cognios Capital LLC bought a new position in DexCom in the 1st quarter valued at about $26,000. Nvwm LLC purchased a new stake in DexCom in the 1st quarter valued at about $27,000. Duncker Streett & Co. Inc. purchased a new stake in DexCom in the 2nd quarter valued at about $41,000. Finally, Weaver Consulting Group purchased a new stake in DexCom in the 1st quarter valued at about $27,000. 97.08% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What is the S&P/TSX Index?

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.